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Screening for Latent 
Tuberculosis (TB) Infection in 
Low TB Incidence Countries
To the Editor—Ronald et al [1] present 
an analysis using data from individuals 
who migrated to British Colombia, 
Canada. They show that the applica-
tion of World Health Organization 
recommendations on screening close tu-
berculosis (TB) contacts or individuals 
with specific medical risk factors for la-
tent tuberculosis infection (LTBI) would 
have a minimal impact on the number of 
TB cases in migrants, and conclude that 
other risk groups must be targeted for 
LTBI screening to progress towards TB 
elimination: that is, migrants from coun-
tries with high TB incidences.
Recently, the European Centre for 
Disease Prevention and Control published 
its guidance on the programmatic man-
agement of LTBI [2]. Although this guid-
ance was developed to support European 
Union and European Economic Area 
Member States in the decision-making 
process underlying the implementation 
of LTBI programmatic management, we 
consider that the identified options for 
LTBI screening are applicable to other 
countries with low TB incidences.
A deterministic mathematical model 
was developed to support the guidance 
development. It included various at-risk 
populations [3, 4]—people who inject 
drugs, homeless people, prisoners, and 
migrants from countries with high TB 
incidences (>50/100  000 population)—
to study the effect of LTBI screening and 
treatment strategies on TB incidences. 
The model was used with data from the 
Netherlands, the Czech Republic, Portugal, 
and Spain: four countries with different ep-
idemiological settings. Screening migrants 
at entry for LTBI was predicted to result in 
a 17–20% decrease in the pulmonary TB 
incidence after 20 years in the Netherlands; 
in the other countries, the decreases were 
projected to be less than 10% [3].
Our threshold for defining countries 
of origin with high TB incidences was 
substantially lower than the threshold 
of 200/100 000 used by Ronald et al [1]. 
Also, we included the suboptimal sensi-
tivity and specificity of diagnostic tests 
for LTBI in our model calculations, 
assumed that only 80–95% of the persons 
diagnosed with LTBI would complete pre-
ventive treatment, and considered averted 
secondary cases (through decreased 
transmission), thus arriving at a more re-
alistic estimate of the effect of screening 
for LTBI.
Just as Roland et  al [1] did, we 
concluded that screening at entry is 
a more feasible option, compared to 
screening of migrants already residing in 
the country, as has been applied in other 
modelling studies [5, 6]. In the United 
Kingdom, expanded entry screening was 
tested by screening migrants from high-
incidence countries that had entered the 
United Kingdom within the prior 5 years 
[7]. In this study, only 40% of migrants 
were tested by interferon-gamma release 
assay. Overall, screening directly after 
migration resulted in a higher coverage 
[8] and is probably easier to implement, 
compared to screening migrants that 
are already in the country. As TB often 
develops shortly after a migrant’s ar-
rival in their host country, it might also 
be more cost-effective to focus on new 
entrants to the country [9].
Next to other studies, the data analysis 
by Ronald et  al [1] provides insights 
to further decision making on the best 
LTBI screening strategy. However, real 
breakthroughs in the management of LTBI 
will require better tests and continued 
work on shorter treatment regimens [10].
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Chagas Disease Endemism in 
the United States
To the Editor—We read with interest 
the article “Prevalence of Chagas Disease 
Among Family Members of Previously 
Diagnosed Patients in Los Angeles, 
California” by Hernandez et  al [1]. As 
noted by the authors, in the absence of 
systematic screening or surveillance, 
Chagas disease (CD) will continue to be 
underdiagnosed in the United States and 
its prevalence underestimated.
By screening relatives of CD patients, 
Hernandez et  al were able to identify 
family members as a high-risk group, 
with CD infection confirmed in 7.4% of 
the individuals screened. Only 4 of the 
14 cases identified were maternal off-
spring (likely congenital transmission). 
CD prevalence was more than 7 times 
higher in close relatives, emphasizing 
important risk factors such as shared 
housing or environment [1]. Currently, 
most CD cases diagnosed in the United 
States are presumed to have become 
infected elsewhere or by congenital 
transmission [2]. However, consider-
able evidence supports the concurrence 
of factors needed to establish vectorial 
transmission and endemicity of CD in 
the United States.
CD is caused by infection with the para-
site Trypanosoma cruzi, following contact 
with feces of an infected triatomine bug, 
usually after a bug bite. As of 2014, 11 spe-
cies of triatomine bugs had been reported 
in 27 mainland US states and Hawaii [3, 
4], including known competent vectors 
of T.  cruzi such as Triatoma sanguisuga, 
Triatoma gerstaeckeri, Triatoma protracta, 
and Triatoma leticularia, which are widely 
distributed in the southern United States, 
notably in Florida and Texas [3, 4]. Many 
are anthropophilic, and in some states, 
like Texas, at least 50% of triatomine bugs 
have been reported to be infected with 
T. cruzi [5].
Furthermore, numerous mamma-
lian wildlife and synthanthropic species 
in the United States have been found 
to be infected with T. cruzi, including 
packrats, wood rats, raccoons, skunks, 
opossums, and armadillos, serving as di-
sease reservoirs. Most importantly, CD 
has been found in domestic and working, 
as well as stray dogs [6–8], colocalizing the 
parasite in close proximity to vulnerable 
populations in suburban and rural areas. 
By linking the zoonotic/peridomestic and 
domestic ecotopes of T. cruzi, CD in do-
mestic dogs is estimated to increase human 
infection risk by 3- to 5-fold [9]. Because 
CD in animals is not a reportable condi-
tion in many states [6], the true number 
of canine cases may be underestimated; 
assessing CD seroprevalence in dogs could 
be useful as an potential bioindicator of 
parasite prevalence and persistence.
We note that Hernandez et al did not 
indicate whether the specific T. cruzi dis-
crete typing units (DTUs) were deter-
mined for their CD cases. Determination 
of the DTU may be important both 
epidemiologically and for patient man-
agement. For example, TcI DTU, the 
most prevalent circulating parasite strain 
in the United States, is associated with 
intrinsic resistance to benznidazole [10], 
bringing into consideration emerging 
therapeutic options such as fexinidazole 
or benzofuran derivatives and azoles.
Thus far, a limited number of human 
CD cases have been proven to be 
US-acquired. However, the coexistence of 
competent disease vectors and numerous 
mammalian reservoirs serve as impor-
tant eco-epidemiological contributors for 
risk of human transmission and infection 
in the United States.
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